Welcome to our dedicated page for Immatics N.V SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning hundreds of pages to see whether Immatics still has cash to fund its next TCER® trial or how collaboration revenue affects runway can feel impossible. The company’s biotech disclosures combine scientific jargon with intricate milestone accounting—making each Immatics SEC filing a daunting read.
Stock Titan solves that problem. Our AI-powered summaries turn the Immatics annual report 10-K simplified into a concise overview of cash burn and pipeline status, while every Immatics quarterly earnings report 10-Q filing is annotated with margin trends and R&D detail. Real-time alerts flag Immatics Form 4 insider transactions seconds after they hit EDGAR, so you never miss executive stock moves before critical data releases.
- Immatics insider trading Form 4 transactions parsed into easy-to-filter tables
- Immatics proxy statement executive compensation distilled to pay vs. performance metrics
- Immatics 8-K material events explained with plain-English AI notes on trial setbacks or partnership wins
- Side-by-side Immatics earnings report filing analysis across quarters to spot cash-runway shifts
Whether you’re understanding Immatics SEC documents with AI for the first time or monitoring seasoned positions, our platform delivers:
Comprehensive coverage of every form type, real-time updates as they post to EDGAR, and expert context that links pipeline science to financial impact. Gain clarity on Immatics executive stock transactions Form 4, uncover hidden risk factors, and track milestones without wading through technical prose. Immatics filings, explained simply—so you can focus on making informed decisions.
Baker Bros. Advisors and affiliated persons report beneficial ownership of 10,168,901 ordinary shares of Immatics N.V., representing 8.4% of the company’s outstanding common stock based on 121,550,169 shares outstanding as reported in the issuer's public filing. The reported holdings are held by two funds (Life Sciences and 667) for which the adviser has sole voting and dispositive power, with 9,354,564 shares held by Life Sciences and 814,337 shares held by 667. This filing amends prior Schedule 13G disclosures and clarifies ownership and control relationships among the adviser, its GP and two individual reporting persons.
This Schedule 13G/A reports that Suvretta Capital Management, LLC and Aaron Cowen each have shared beneficial ownership of 12,030,129 ordinary shares of Immatics N.V., representing 9.9% of the class. Averill Master Fund, Ltd. reports shared beneficial ownership of 10,623,778 shares, representing 8.7% of the class. The filing shows no sole voting or sole dispositive power for any reporting person; all listed voting and dispositive power is shared. The filing states the securities are directly owned by advisory clients of Suvretta, and the reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
Wellington Management and related entities report beneficial ownership of 5,318,624 shares of Immatics N.V. common stock, representing approximately 4.38% of the class. The filing discloses no sole voting or dispositive power; voting is held as shared voting power of 4,545,848 shares and shared dispositive power of 5,318,624 shares. These shares are owned of record by clients of Wellington investment advisers.
The statement clarifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control; no client is identified as having the right to dividends or sale proceeds for more than 5% of the class.
FAQ
What is the current stock price of Immatics N.V (IMTX)?
What is the market cap of Immatics N.V (IMTX)?
